Protocols

The FDA's June 2026 wave of 25 warning letters to telehealth companies — combined with its standing position that retatrutide cannot be legally compounded — materially narrows the landscape for practitioners using GLP-1 peptide protocols. Compounded semaglutide and tirzepatide now face tighter sourcing requirements, while retatrutide products outside clinical trials carry no regulatory pathway whatsoever.

Compounded semaglutide occupies an increasingly narrow legal corridor in mid-2026. Bulk shortage-based compounding ended in April–May 2025, the FDA logged more than 1,700 adverse events by May 21, 2026, and on April 30, 2026 proposed excluding semaglutide from the 503B bulks list entirely. A limited patient-specific 503A pathway survives under strict documented-need conditions.

A 2026 review published in International Journal of Molecular Sciences (MDPI) synthesises preclinical evidence showing that BPC-157 — a 15-amino-acid pentadecapeptide derived from human gastric juice — accelerates tissue repair through angiogenesis, collagen synthesis, and FAK-paxillin signalling, while also attenuating pain via nitric oxide pathway modulation and central nociceptive mechanisms.

Animal studies do not confirm that TB-500 directly reactivates dormant tumors in humans, but they raise a biologically credible concern. Preclinical data show that thymosin beta-4 — the endogenous peptide TB-500 mimics — upregulates VEGF, activates pro-invasive signaling in cancer cell lines, and is overexpressed in several human tumor types. No controlled human trial has tested this risk.

PT-141 (bremelanotide) carries a formal FDA contraindication in patients with known cardiovascular disease or uncontrolled hypertension. In controlled trials, the 1.75 mg subcutaneous dose transiently raised mean systolic blood pressure by approximately 3 mmHg and lowered heart rate by roughly 2 bpm — effects that resolve within 12 hours but pose disproportionate risk in patients with compromised cardiac reserve.